

# **Optimizing the aggregation propensity of therapeutic monoclonal antibodies against cancer and autoimmune diseases: a computational study**

Anna-Isabella G. Rerra<sup>1</sup>, Vasiliki P. Grimanelli<sup>1</sup>, Nikos C. Papandreou, Stavros J. Hamodrakas\*

Department of Cell Biology and Biophysics, Faculty of Biology, University of Athens,

Panepistimiopolis, Athens 157 01, Greece

## **Emails:**

[annarerra@biol.uoa.gr](mailto:annarerra@biol.uoa.gr)

[vgrimanelli@biol.uoa.gr](mailto:vgrimanelli@biol.uoa.gr)

[npapand@biol.uoa.gr](mailto:npapand@biol.uoa.gr)

[shamodr@biol.uoa.gr](mailto:shamodr@biol.uoa.gr)

\*Corresponding Author: Department of Cell Biology and Biophysics, Faculty of Biology,

University of Athens, Panepistimiopolis, Athens 157 01, Greece

email: [shamodr@biol.uoa.gr](mailto:shamodr@biol.uoa.gr)

<sup>1</sup> Equally contributing authors

**RUNNING TITLE:** *Optimizing the aggregation propensity of monoclonal antibodies*

**KEYWORDS:** Aggregation-prone regions; Monoclonal antibodies; Aggregation propensity; Cancer; Autoimmune diseases

**ABBREVIATIONS:** mAbs, monoclonal antibodies; CDRs, Complementarity Determining Regions; FDA, U.S. Food and Drug Administration; L1, light loop 1; L2, light loop 2; L3, light loop 3; H1, heavy loop 1; H2, heavy loop 2; H3, heavy loop 3.

**NOTES:** *The authors declare no competing interests.*

## **Abstract**

Monoclonal antibodies (mAbs) represent the most promising and rapidly growing class of therapeutic compounds for treating a wide variety of human chronic and acute diseases. Despite their benefits, a major drawback in the exploitation of antibodies is their tendency to form aggregates. As a result, severe immunological reactions in patients have been recorded.

In this study, we investigated the susceptibility of a set of therapeutic monoclonal antibodies to form aggregates. We selected antibodies that have all been approved by the U. S. Food and Drug Administration and are indicated for the treatment of various types of cancer and autoimmune diseases. The AMYLPRED 2 consensus method was used to predict ‘aggregation-prone’ regions on the surface of these proteins.

These regions are conserved and observed in almost all monoclonal antibodies commercially available. Considering the amino acid sequences of these antibodies, common groups of ‘aggregation-prone’ regions were identified, called clusters. We successfully reduced or even fully eliminated ‘aggregation-prone’ groups (clusters) by specific ‘mutations’ of amino acids with exposed side chains. This information may be useful in future studies of monoclonal antibodies by improving existing therapeutic products or by designing novel ones.

## Introduction

Monoclonal antibodies (mAbs) are tetramers of two identical pairs of polypeptide chains, the heavy and the light chains [1]. The light chain consists of one variable and one constant domain and the heavy chain consists of one variable and three or more constant domains [1]. All the domains have a similar tertiary structure called immunoglobulin fold, which is characterized by two anti-parallel beta sheets [2]. The antigen-binding site consists of six loops, three from the light chain and three from the heavy chain [3]. These loops are also known as complementarity determining regions (CDRs) and they are responsible for the recognition and the binding between antibody and antigen [4].

Given almost any substance, it is possible to produce monoclonal antibodies that specifically bind to it [5]. MAbs are made by identical immune cells that are clones of a unique parent B-cell, have monovalent affinity, bind to the same epitope and can be reproduced endlessly *in vitro* [6].

They are used in treatment schemes for autoimmune [7], cardiovascular [8] and infectious diseases [9], cancers [10,11] and others. They can also be used as diagnostic [12] and biotechnological tools [13].

Monoclonal antibodies in high concentrations, in their storage and usage, form aggregates [14], which are an increasing concern in therapeutic development. Protein aggregation causes side effects and immunogenic responses in clinical trials [15]. Aggregates may also result in reduction of antibody therapeutic activity, while severe immunological reactions in patients have been recorded [16]. Thus, it is important to understand the aggregation mechanisms of mAbs under different circumstances [17] and their potential biological implications in the pharmaceutical industry in order to improve their efficacy and make them successful biopharmaceutical products [18].

Several computational studies have been carried out and a variety of monoclonal antibodies have been extensively studied and engineered [19]. A number of computational tools are also available [20] to predict aggregation-prone regions in therapeutic proteins. These tools focus on predicting the aggregation-prone regions (small peptides) and finding the potential sequence and structure factors that contribute toward aggregation formation in proteins [21]. As a result, a number of monoclonal antibodies have been improved, used again and for other cases too.

Taking into account all these insights, our purpose was to propose novel models of therapeutic monoclonal antibodies with optimized aggregation propensity, based on an amino acids substitution approach. Our findings can be applied on rational design of novel therapeutic candidates or improvement of existing bio-therapeutics.

## Materials and methods

### Dataset collection

In order to study the monoclonal antibodies, we carried out an extensive research in the literature and available databases. We analyzed antibodies that have been approved by the U.S. Food and Drug Administration (FDA) and have been indicated for the treatment of various acute and chronic diseases like cancer and autoimmune diseases. They are all IgG1 kappa immunoglobulins and they have several and different mechanisms of action.

We collected the amino acid sequences of antibodies from the Protein Data Bank [22]. We obtained also the three-dimensional structures of antibodies from the Protein Data Bank (PDB ID for Alemtuzumab: **1CE1**, PDB ID for Bevacizumab: **1BJ1**, PDB ID for Cetuximab: **1YY8**, PDB ID for Ofatumumab: **3GIZ**, PDB ID for Pertuzumab: **1L71**, PDB ID for Rituximab: **2OSL**, PDB ID for Trastuzumab: **1N8Z**, PDB ID for Adalimumab: **3WD5**, PDB ID for Infliximab: **4G3Y**, PDB ID for Natalizumab: **4IRZ**, PDB ID for Ustekinumab: **3HMX**).

Additional information about the monoclonal antibodies was obtained from the Drug Bank [23] and the Monoclonal Antibodies Database, part of the IMGT®, the international ImMunoGeneTics information system® [24] in order to perform sequence analysis.

### Monoclonal antibodies against cancer

Detailed information about monoclonal antibodies against cancer used in this study is presented in Table 1.

## **Monoclonal antibodies against autoimmune diseases**

Detailed information about monoclonal antibodies against autoimmune diseases used in this study is presented in Table 2.

## **Aggregation-prone regions**

In order to predict ‘aggregation-prone’ regions on the surface of antibodies, we used AMYLPRED2 [25], a consensus method, which predicts ‘aggregation-prone’ peptides on an amino acid sequence, from sequence alone, developed in our lab. For each monoclonal antibody, the algorithm was applied to the amino acid sequence of each chain separately.

Furthermore, sequence alignments of heavy chains and light chains were performed utilizing ClustalW [26], to identify similarities and differences between the antibodies used.

## **Criteria of the amino-acid mutation**

Three criteria were followed in order to select the amino acids that may be substituted by others in the amino acid sequences of the monoclonal antibodies of the dataset.

The first criterion was the accessibility of these amino acids to the solvent in the 3D-structure. It is undesirable to change amino acids that are not on the surface of the protein, because these changes will probably affect the 3D-structure and the stability of the molecule. For this reason, we located the amino acid residues of the antibodies exposed to the solvent with the help of the DSSP algorithm [27]. Residues that are in contact with at least two molecules of water and they are predicted by AMYLPRED2 [25] to be in ‘aggregation-prone’ regions, were selected as possible candidates to be substituted by others.

The second criterion was that the residues to be substituted should not be found in complementarity determining regions (CDRs). Residues in these regions are responsible for the recognition and the interaction with the antigen-target. For these reason, any change in these regions may cause unexpected effects to the functionality of the antibody.

The third criterion was to replace amino acid residues with exposed side chains, in the predicted ‘aggregation-prone’ regions, considering the experimental aggregation propensities of the 20 natural amino acids [28]. According to the propensities, residues that are ‘aggregation-prone’ have positive values and those that are not have negative values. The higher the tension to form aggregates, the greater the positive value is and the same applies for the negative values, respectively.

We also took into account the 3D-structure (Fab fragment) of the antibodies in order to be certain that our ‘mutations’ do not affect overall the 3D-structure.

## Clusters

After performing sequence alignments of all the monoclonal antibodies in the dataset, for the light (Fig. 1) and the heavy (Fig. 2) chain separately, we discovered some common groups of ‘aggregation-prone’ regions in the amino acid sequences of the antibodies that are present in almost all the monoclonal antibodies that are now on the market, against cancer and autoimmune diseases, in a similar way as it was done in [29].

These ‘aggregation-prone’ regions were grouped into clusters according to their positions in the 3D-structure (Figs. 3A, B). With specific changes of amino acid residues, only in the peptides that are present in ‘aggregation-prone’ regions, we successfully diminished ‘aggregation-prone’ clusters or even made them to disappear completely (Figs. 3A, B).

The procedure of selecting the amino acids that will substitute the initial ones was really tedious, because of the fact that for each residue, in each chain, in each antibody of the dataset all possibilities were tested manually. Consequently, residues with exposed side chains, in ‘aggregation-prone’ regions, were substituted by others with lower tendency to form aggregates, but with similar physicochemical properties and the potential to form aggregates was reduced or even eliminated in some cases.

### **Novel models - Evaluation and improvements**

After the substitutions, novel amino acid sequences were created. The AMYLPRED2 [25] consensus method was used again to predict ‘aggregation-prone’ regions in the novel amino acid sequences.

The Modeller 9.13 [30] software was used for homology modeling and novel models of the ‘mutated’ proteins were calculated, utilizing as templates the native structures. The side chains of the ‘mutated’ residues were examined and optimized, in order to ensure that the side chains are still exposed and to avoid steric hindrance. This was done utilizing Chimera 1.8 [31] and its capability to minimize the energy of the structure. The PROCHECK [32] and WHAT\_CHECK [33], from software WHAT IF [34], algorithms were used to check the validity and the quality of the novel models. [Special care was taken so that the CDR conformations remain unaltered in the novel models.](#)

## Results

The sequence alignments of all monoclonal antibodies in the dataset, for the light and the heavy chain separately, are presented in Figs. 1 and 2, respectively. The CDRs for light and heavy chain are named L1, L2, L3 and H1, H2, H3 accordingly. The ‘aggregation-prone’ regions, that AMYLPRED2 [25] consensus method predicted, are also illustrated and grouped into clusters according to their position in the 3D-structure (Figs. 3A and 3B, BEFORE and Figs. 1 and 2). These clusters were called Cluster1 – Cluster5. Only two specific examples for the monoclonal antibodies RITUXIMAB and ADALIMUMAB are shown in Figs. 3A and 3B.

Performing specific changes of amino acid residues, only in the clusters, ‘aggregation-prone’ clusters were successfully diminished or even eliminated completely (shown explicitly in Figs. 3A and 3B, AFTER).

The clusters that we grouped the common ‘aggregation-prone’ regions, according to the 3D-structure of the proteins, are also presented in Table 3 in the column ‘Clusters’. The column ‘Regions’ contains the common ‘aggregation-prone’ regions, the column ‘Chain’ the chain of the regions and the column ‘Peptides’ presents the different peptides that were found in the common ‘aggregation-prone’ regions. The amino acids that were substituted are illustrated in bold and they are underlined. The column ‘After Substitutions’ contains the peptides after the substitutions. In some cases, some ‘aggregation-prone’ peptides were eliminated completely and this is depicted with the symbol ( $\sqrt{\phantom{x}}$ ). In other cases the ‘aggregation-prone’ peptides were diminished sufficiently and the peptides that remain are presented in the table.

Taking a closer look to the amino acids that were substituted, the amino acids Threonine (THR, T) and the amino acid Serine (SER, S) were mostly substituted. Other amino acids that were considerably substituted by others, were the amino acids Tyrosine (TYR, Y), Valine (VAL, V), Isoleucine (ISO, I) and Leucine (LEU, L). Thus, polar and hydrophobic amino acids which

seem to favor aggregation should be substituted by other polar or charged amino acids, considering the experimental aggregation propensities of the 20 natural amino acids [28].

Every ‘aggregation-prone’ peptide, which belongs to a cluster, with a combination of one or two substitutions, will no longer be ‘aggregation-prone’. There are several potential combinations of substitutions that may bring the desirable result. The novel models that are proposed, after the substitutions, will be less ‘aggregation-prone’ and should not provoke immunological reactions to patients. This remains to be proven by more refined experimental work.

We conclude that, comparing the space-filling models before and after the substitutions, with specific replacements of exposed amino acid residues, only in the clusters that contain common ‘aggregation-prone’ regions, the potential of antibodies to form aggregates will be reduced or even eliminated. Accordingly, their aggregation propensity should also be reduced without affecting the potency of the bio-therapeutics.

## Discussion

The mechanisms of protein aggregation are very complicated. Protein aggregation and the problems it causes in biopharmaceutics are discussed in detail, in a relatively recent excellent review [16]. The aggregation of a protein in solution is driven by intrinsic and extrinsic factors [29]. The sequences and structures of Fab commercial and non-commercial antibodies were studied in detail by these authors, utilizing the computational tools TANGO [35] and PAGE [36], to identify potential aggregation-prone regions in these antibodies (intrinsic aggregation factors). They discovered in their dataset 2 to 8 aggregation-prone motifs per heavy and light chain pair. Some of these motifs were located in variable domains, mainly in CDRs [29].

In this work, we collected all mAbs against cancer and autoimmune diseases, with solved crystal structures from the PDB [22], and with aid of AMYLPRED2 [25], a consensus algorithm, which combines eleven (11) individual algorithms for the prediction of aggregation-prone sequences in globular proteins (including TANGO), we predicted aggregation-prone regions in the light and heavy chains of these antibodies.

We should mention here that, AMYLPRED2 (and its previous version AMYLPRED) have been used with considerable success, in recent years, for the prediction of aggregation-prone peptides in amyloidogenic proteins [37-41]. The predicted aggregation-prone peptides have been synthesized and experimentally shown to self-assemble (aggregate) to form amyloid-like fibrils. AMYLPRED2, freely available for academic users, is one of the most successful algorithms for the prediction of aggregation-prone segments (peptides) in globular proteins, as can be seen in the original publication [25].

The idea of predicting aggregation-prone regions of light and heavy chains of mAbs was to try to identify clusters of aggregation-prone regions that could create aggregation “hot-spots” on

the surface of these proteins. These aggregation “hot-spots” could drive the mAbs to aggregate. Performing suitably selected mutations on these “hot-spots”, we managed to diminish or even completely eliminate them. Special care was taken that the performed mutations did not affect the conformations of the CDRs of the antibodies. Also, care was taken that the mutations were not performed to amino acids contained in aggregation-prone regions, which overlap with CDRs.

This computational study can be generalized in other monoclonal antibodies that are used therapeutically for other diseases. Work is in progress along these lines (In preparation). It should be emphasized that experiments should be performed to experimentally test the monoclonal antibody variants predicted in this study and verify that have lower aggregation propensities and also ensure that there will be no side effects. A general computational method for a semi-automated optimization of the aggregation propensity of all monoclonal antibodies will be proposed soon (work in preparation).

We hope and anticipate that the combination of predictions, experiments and molecular models of the candidate targets can be applied on novel and existing bio-therapeutics with promising results. Finally, the continuous development and application of rational protein design technology will enable improvements in the efficacy and safety of protein therapeutics.

**Acknowledgements**

We thank the University of Athens for support. We also thank the reviewers of this manuscript for their very useful and constructive criticism.

**Author contributions**

A.G.R., V.P.G. and N.C.P. collected the data, performed calculations and evaluated the results.

S.J.H. supervised the whole project and evaluated the results. All authors contributed to the writing of the manuscript. All authors have read and approve the final version of the manuscript.

## REFERENCES

1. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. *Nat Rev Drug Discov*. 2010;9(4):325-38.
2. Bork P, Holm L, Sander C. The immunoglobulin fold. Structural classification, sequence patterns and common core. *J Mol Biol*. 1994;242(4):309-20.
3. Al-Lazikani B, Lesk AM, Chothia C. Standard conformations for the canonical structures of immunoglobulins. *J Mol Biol*. 1997;273(4):927-48.
4. Wu TT, Kabat EA. An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. *J Exp Med*. 1970;132(2):211-50.
5. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature*. 1975;256(5517):495-7.
6. Lipman NS, Jackson LR, Trudel LJ, Weis-Garcia F. Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources. *ILAR J*. 2005;46(3):258-68.
7. Bruno V, Battaglia G, Nicoletti F. The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases. *Neurological Sciences*. 2011;31 Suppl 3:283-8.
8. Catapano AL, Papadopoulos N. The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. *Atherosclerosis*. 2013;228(1):18-28.
9. Ter Meulen J. Monoclonal antibodies in infectious diseases: clinical pipeline in 2011. *Infect Dis Clin North Am*. 2011;25(4):789-802.
10. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. *Nat Biotechnol*. 2005;23(9):1073-8.
11. Modjtahedi H, Ali S, Essapen S. Therapeutic application of monoclonal antibodies in cancer: advances and challenges. *Br Med Bull*. 2012;104:41-59.
12. Siddiqui MZ. Monoclonal antibodies as diagnostics; an appraisal. *Indian Journal of Pharmaceutical Sciences*. 2010;72(1):12-7.
13. Marenco de la Fuente JL. [Applications of monoclonal antibodies and biotechnology products in the treatment of chronic inflammatory diseases]. *Rev Clin Esp*. 2005;205(3):127-36.
14. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. *Br J Pharmacol*. 2009;157(2):220-33.
15. Rosenberg AS. Effects of protein aggregates: an immunologic perspective. *AAPS J*. 2006;8(3):E501-7.
16. Wang W. Protein aggregation and its inhibition in biopharmaceutics. *Int J Pharm*. 2005;289(1-2):1-30.
17. Roberts CJ. Therapeutic protein aggregation: mechanisms, design, and control. *Trends Biotechnol*. 2014;32(7):372-80.
18. Marshall SA, Lazar GA, Chirino AJ, Desjarlais JR. Rational design and engineering of therapeutic proteins. *Drug Discov Today*. 2003;8(5):212-21.
19. Hwang I, Park S. Computational design of protein therapeutics. *Drug Discov Today Technol*. 2008;5(2-3):e43-8.
20. Agrawal NJ, Kumar S, Wang X, Helk B, Singh SK, Trout BL. Aggregation in protein-based biotherapeutics: computational studies and tools to identify aggregation-prone regions. *J Pharm Sci*. 2011;100(12):5081-95.
21. Chennamsetty N, Helk B, Voynov V, Kayser V, Trout BL. Aggregation-prone motifs in human immunoglobulin G. *J Mol Biol*. 2009;391(2):404-13.
22. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H et al. The Protein Data Bank. *Nucleic Acids Res*. 2000;28(1):235-42.
23. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A et al. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. *Nucleic Acids Res*. 2011;39(Database issue):D1035-41.
24. Lefranc MP, Giudicelli V, Ginestoux C, Jabado-Michaloud J, Folch G, Bellahcene F et al. IMGT, the international ImMunoGeneTics information system. *Nucleic Acids Res*. 2009;37(Database issue):D1006-12.
25. Tsolis AC, Papandreou NC, Ionomidou VA, Hamodrakas SJ. A consensus method for the prediction of 'aggregation-prone' peptides in globular proteins. *PloS One*. 2013;8(1):e54175.

26. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H et al. Clustal W and Clustal X version 2.0. *Bioinformatics*. 2007;23(21):2947-8.
27. Kabsch W, Sander C. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. *Biopolymers*. 1983;22(12):2577-637.
28. Sanchez de Groot N, Pallares I, Aviles FX, Vendrell J, Ventura S. Prediction of "hot spots" of aggregation in disease-linked polypeptides. *BMC Structural Biology*. 2005;5:18.
29. Wang X, Das TK, Singh SK, Kumar S. Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies. *mAbs*. 2009;1(3):254-67.
30. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. *J Mol Biol*. 1993;234(3):779-815.
31. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC et al. UCSF Chimera--a visualization system for exploratory research and analysis. *Journal of Computational Chemistry*. 2004;25(13):1605-12.
32. Laskowski RA, Rullmannn JA, MacArthur MW, Kaptein R, Thornton JM. AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. *J Biomol NMR*. 1996;8(4):477-86.
33. Hoof RW, Vriend G, Sander C, Abola EE. Errors in protein structures. *Nature*. 1996;381(6580):272.
34. Vriend G. WHAT IF: a molecular modeling and drug design program. *J Mol Graph*. 1990;8(1):52-6, 29.
35. Fernandez-Escamilla AM, Rousseau F, Schymkowitz J, Serrano L. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. *Nat Biotechnol*. 2004;22(10):1302-6.
36. Tartaglia GG, Cavalli A, Pellarin R, Cafisch A. Prediction of aggregation rate and aggregation-prone segments in polypeptide sequences. *Protein Sci*. 2005;14(10):2723-34.
37. Iconomidou VA, Leontis A, Hoenger A, Hamodrakas SJ. Identification of a novel 'aggregation-prone'/'amyloidogenic determinant' peptide in the sequence of the highly amyloidogenic human calcitonin. *FEBS Lett*. 2013;587(6):569-74.
38. Louros NN, Iconomidou VA, Tsiolaki PL, Chrysina ED, Baltatzis GE, Patsouris ES et al. An N-terminal pro-atrial natriuretic peptide (NT-proANP) 'aggregation-prone' segment involved in isolated atrial amyloidosis. *FEBS Lett*. 2014;588(1):52-7.
39. Louros NN, Tsiolaki PL, Griffin MD, Howlett GJ, Hamodrakas SJ, Iconomidou VA. Chameleon 'aggregation-prone' segments of apoA-I: A model of amyloid fibrils formed in apoA-I amyloidosis. *Int J-Biol Macromol*. 2015;79:711-8.
40. Louros NN, Tsiolaki PL, Zompra AA, Pappa EV, Magafa V, Pairas G et al. Structural studies and cytotoxicity assays of "aggregation-prone" IAPP8-16 and its non-amyloidogenic variants suggest its important role in fibrillogenesis and cytotoxicity of human amylin. *Biopolymers*. 2015;104(3):196-205.
41. Tsiolaki PL, Louros NN, Hamodrakas SJ, Iconomidou VA. Exploring the 'aggregation-prone' core of human Cystatin C: A structural study. *J Struct Biol*. 2015;191(3):272-80.
42. Buggins AG, Mufti GJ, Salisbury J, Codd J, Westwood N, Arno M et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. *Blood*. 2002;100(5):1715-20.
43. Dumont FJ. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond. *Expert Rev Anticancer Ther*. 2002;2(1):23-35.
44. Fox EJ. Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis. *Expert Rev Neurother*. 2010;10(12):1789-97.
45. James LC, Hale G, Waldmann H, Bloomer AC. 1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen. *J Mol Biol*. 1999;289(2):293-301.
46. Keating M, Hallek M. Alemtuzumab, the first monoclonal antibody (MAb) directed against CD52. *Med Oncol*. 2002;19 Suppl:S1-2.
47. Quintas-Cardama A, O'Brien S. Targeted therapy for chronic lymphocytic leukemia. *Target Oncol*. 2009;4(1):11-21.
48. Burkhardt JK, Riina H, Shin BJ, Christos P, Kesavabhotla K, Hofstetter CP et al. Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival. *World Neurosurg*. 2012;77(1):130-4.

49. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. *N Engl J Med*. 2014;370(8):699-708.
50. Los M, Roodhart JM, Voest EE. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. *Oncologist*. 2007;12(4):443-50.
51. Muller YA, Chen Y, Christinger HW, Li B, Cunningham BC, Lowman HB et al. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 Å resolution and mutational analysis of the interface. *Structure*. 1998;6(9):1153-67.
52. Semenza GL. A new weapon for attacking tumor blood vessels. *N Engl J Med*. 2008;358(19):2066-7.
53. Velcheti V, Viswanathan A, Govindan R. The proportion of patients with metastatic non-small cell lung cancer potentially eligible for treatment with bevacizumab: a single institutional survey. *J Thorac Oncol*. 2006;1(5):501.
54. Downward J, Parker P, Waterfield MD. Autophosphorylation sites on the epidermal growth factor receptor. *Nature*. 1984;311(5985):483-5.
55. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. *Cancer Cell*. 2005;7(4):301-11.
56. Messersmith WA, Ahnen DJ. Targeting EGFR in colorectal cancer. *N Engl J Med*. 2008;359(17):1834-6.
57. Oda K, Matsuoka Y, Funahashi A, Kitano H. A comprehensive pathway map of epidermal growth factor receptor signaling. *Mol Syst Biol*. 2005;1:2005 0010.
58. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. *N Engl J Med*. 2008;359(11):1116-27.
59. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R et al. ErbB receptors: from oncogenes to targeted cancer therapies. *J Clin Invest*. 2007;117(8):2051-8.
60. Du J, Yang H, Guo Y, Ding J. Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. *Mol Immunol*. 2009;46(11-12):2419-23.
61. Lin TS. Ofatumumab: a novel monoclonal anti-CD20 antibody. *Pharmgenomics Pers Med*. 2010;3:51-9.
62. Macardle PJ, Nicholson IC. Cd20. *J Biol Regul Homeost Agents*. 2002;16(2):136-8.
63. Tedder TF, Streuli M, Schlossman SF, Saito H. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. *Proc Natl Acad Sci U S A*. 1988;85(1):208-12.
64. Traynor K. Ofatumumab approved for advanced CLL. *Am J Health Syst Pharm*. 2009;66(23):2062.
65. Zhang B. Ofatumumab. *MAbs*. 2009;1(4):326-31.
66. Mitri Z, Constantine T, O'Regan R. The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. *Chemother Res Pract*. 2012;2012:743193.
67. Olayioye MA. Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. *Breast Cancer Res*. 2001;3(6):385-9.
68. Vajdos FF, Adams CW, Breece TN, Presta LG, de Vos AM, Sidhu SS. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. *J Mol Biol*. 2002;320(2):415-28.
69. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E et al. Complement activation determines the therapeutic activity of rituximab in vivo. *J Immunol*. 2003;171(3):1581-7.
70. Du J, Wang H, Zhong C, Peng B, Zhang M, Li B et al. Structural basis for recognition of CD20 by therapeutic antibody Rituximab. *J Biol Chem*. 2007;282(20):15073-80.
71. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. *N Engl J Med*. 2004;350(25):2572-81.
72. Grillo-Lopez AJ, White CA, Varns C, Shen D, Wei A, McClure A et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. *Semin Oncol*. 1999;26(5 Suppl 14):66-73.
73. Jaglowski SM, Byrd JC. Rituximab in chronic lymphocytic leukemia. *Semin Hematol*. 2010;47(2):156-69.
74. Scott SD. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma. *Cancer Pract*. 1998;6(3):195-7.
75. Burstein HJ. The distinctive nature of HER2-positive breast cancers. *N Engl J Med*. 2005;353(16):1652-4.

76. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, Jr. et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. *Nature*. 2003;421(6924):756-60.
77. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. *Nat Med*. 2000;6(4):443-6.
78. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V et al. Trastuzumab containing regimens for early breast cancer. *Cochrane Database Syst Rev*. 2012;4:CD006243.
79. Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. *Oncogene*. 2000;19(53):6115-21.
80. Alwawi EA, Mehlis SL, Gordon KB. Treating psoriasis with adalimumab. *Ther Clin Risk Manag*. 2008;4(2):345-51.
81. Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. *Rheumatology (Oxford)*. 2007;46(7):1191-9.
82. Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. *Arthritis Rheum*. 2007;56(2):476-88.
83. Hu S, Liang S, Guo H, Zhang D, Li H, Wang X et al. Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor alpha-associated diseases from a molecular view. *J Biol Chem*. 2013;288(38):27059-67.
84. Lichtenstein GR, Panaccione R, Mallarkey G. Efficacy and safety of adalimumab in Crohn's disease. *Therap Adv Gastroenterol*. 2008;1(1):43-50.
85. Marzan KA. Role of adalimumab in the management of children and adolescents with juvenile idiopathic arthritis and other rheumatic conditions. *Adolesc Health Med Ther*. 2012;3:85-93.
86. McDermott E, Murphy S, Keegan D, O'Donoghue D, Mulcahy H, Doherty G. Efficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis. *J Crohns Colitis*. 2013;7(2):150-3.
87. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum*. 2006;54(7):2136-46.
88. Grainger R, Harrison AA. Infliximab in the treatment of ankylosing spondylitis. *Biologics*. 2007;1(2):163-71.
89. Katsicas MM, Russo RA. Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept. *Clin Exp Rheumatol*. 2005;23(4):545-8.
90. Liang S, Dai J, Hou S, Su L, Zhang D, Guo H et al. Structural basis for treating tumor necrosis factor alpha (TNFalpha)-associated diseases with the therapeutic antibody infliximab. *J Biol Chem*. 2013;288(19):13799-807.
91. Papoutsaki M, Osorio F, Morais P, Torres T, Magina S, Chimenti S et al. Infliximab in psoriasis and psoriatic arthritis. *BioDrugs*. 2013;27 Suppl 1:13-23.
92. Perdriger A. Infliximab in the treatment of rheumatoid arthritis. *Biologics*. 2009;3:183-91.
93. Poggioli G, Laureti S, Campieri M, Pierangeli F, Gionchetti P, Ugolini F et al. Infliximab in the treatment of Crohn's disease. *Ther Clin Risk Manag*. 2007;3(2):301-8.
94. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. *Cytokine*. 1995;7(3):251-9.
95. Wilhelm SM, McKenney KA, Rivait KN, Kale-Pradhan PB. A review of infliximab use in ulcerative colitis. *Clin Ther*. 2008;30(2):223-30.
96. Guagnozzi D, Caprilli R. Natalizumab in the treatment of Crohn's disease. *Biologics*. 2008;2(2):275-84.
97. Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. *Lancet Neurol*. 2011;10(8):745-58.
98. Yu Y, Schurpf T, Springer TA. How natalizumab binds and antagonizes alpha4 integrins. *J Biol Chem*. 2013;288(45):32314-25.

99. Gottlieb A, Narang K. Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential. *Ther Adv Musculoskelet Dis.* 2013;5(5):277-85.
100. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. *N Engl J Med.* 2010;362(2):118-28.
101. Khanna R, Feagan BG. Ustekinumab for the treatment of Crohn's disease. *Immunotherapy.* 2013;5(8):803-15.
102. Luo J, Wu SJ, Lacy ER, Orlovsky Y, Baker A, Teplyakov A et al. Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab. *J Mol Biol.* 2010;402(5):797-812.
103. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. *Lancet Neurol.* 2008;7(9):796-804.

## FIGURE LEGENDS

**Fig. 1.** Sequence alignment of light chains of all the monoclonal antibodies of the dataset. ClustalW was used for the alignment [26]. The molecule name and the PDB ID are mentioned. The three CDRs are highlighted in yellow and named L1, L2 and L3. The predicted aggregation-prone regions are shown in red. The clusters of ‘aggregation-prone’ regions are also indicated (Cluster1, Cluster2, Cluster3, Cluster4).

**Fig. 2.** Sequence alignment of heavy chains of all the monoclonal antibodies of the dataset. ClustalW was used for the alignment [26]. The molecule name and the PDB ID are mentioned. The three CDRs are highlighted in yellow and named H1, H2 and H3. The predicted aggregation-prone regions are in red. The clusters of ‘aggregation-prone’ regions are also indicated (Cluster3, Cluster5).

**Fig. 3.**

**A.** Space-filling models of the monoclonal antibody Rituximab (Rituxan) (PDB ID: 2OSL) produced utilizing the software Chimera 1.8 [31]. The molecule name and the PDB ID are mentioned. Light chain in grey, heavy chain in blue, ‘aggregation-prone’ regions in red, CDRs in yellow, ‘aggregation-prone’ regions in CDRs in cyan and the residues that will be substituted are depicted with green color. The ‘BEFORE’ images illustrate the stage before the substitutions and the names of the clusters, for front and back view. The ‘AFTER’ images represent the structures after the substitutions and the substitutions made (residue that was substituted and position), for front and back view.

**B.** Space-filling models of the monoclonal antibody Adalimumab (Humira) (PDB ID: 3WD5) produced utilizing the software Chimera 1.8 [31]. The molecule name and the PDB ID are mentioned. Light chain in grey, heavy chain in blue, ‘aggregation-prone’ regions in red, CDRs in yellow, ‘aggregation-prone’ regions in CDRs in cyan and the residues that will be substituted are depicted with green color. The ‘BEFORE’ images illustrate the stage before the substitutions and the names of the clusters, for front and back view. The ‘AFTER’ images represent the structures after the substitutions and the substitutions made (residue that was substituted and position), for front and back view



|   |                               |            |           |            |       |            |                                    |      |           |
|---|-------------------------------|------------|-----------|------------|-------|------------|------------------------------------|------|-----------|
| 4 | <b>Ofatumumab</b><br>[60-65]  | ARZERRA®   | Human     | IgG1-kappa | CD20  | 3G1Z       | Chronic<br>lymphocytic<br>leukemia | 2009 | Phase M   |
|   |                               |            |           |            |       |            | Non-Hodgkin's<br>lymphoma          |      | Phase III |
|   |                               |            |           |            |       |            |                                    |      |           |
| 5 | <b>Pertuzumab</b><br>[66-68]  | PERJETA®   | Humanized | IgG1-kappa | ERBB2 | 1L7I, 1S78 | Breast cancer                      | 2012 | Phase M   |
|   |                               |            |           |            |       |            | Prostate cancer                    |      | Phase II  |
|   |                               |            |           |            |       |            |                                    |      |           |
| 6 | <b>Rituximab</b><br>[69-74]   | RITUXAN®   | Chimeric  | IgG1-kappa | CD20  | 2OSL       | Non-Hodgkin's<br>lymphoma          | 1997 | Phase M   |
|   |                               |            |           |            |       |            | Chronic<br>lymphocytic<br>leukemia | 2010 | Phase M   |
|   |                               |            |           |            |       |            |                                    |      |           |
| 7 | <b>Trastuzumab</b><br>[75-79] | HERCEPTIN® | Humanized | IgG1-kappa | ERBB2 | 1N8Z       | Breast cancer                      | 1998 | Phase M   |
|   |                               |            |           |            |       |            | Gastric cancer                     | 2010 | Phase M   |

**Table 2.** Monoclonal antibodies against autoimmune diseases used in this study.

[illegible]

|   |                                |                       |           |            |                |              |                      |           |          |
|---|--------------------------------|-----------------------|-----------|------------|----------------|--------------|----------------------|-----------|----------|
| 3 | <b>Natalizumab</b><br>[96-98]  | TYSABRI®              | Humanized | IgG4       | ITGA4          | 4IRZ         | Multiple sclerosis   | 2004/2006 | Phase M  |
|   |                                |                       |           |            |                |              | Crohn's disease      | 2008      | Phase M  |
|   |                                |                       |           |            |                |              |                      |           |          |
|   |                                |                       |           |            |                |              |                      |           |          |
| 4 | <b>Rituximab</b><br>[69-74]    | RITUXAN®<br>MABTHERA® | Chimeric  | IgG1-kappa | CD20           | 2OSL         | Rheumatoid arthritis | 2006      | Phase M  |
|   |                                |                       |           |            |                |              |                      |           |          |
| 5 | <b>Ustekinumab</b><br>[99-103] | STELARA®              | Human     | IgG1-kappa | IL12A<br>IL12B | 3HMX<br>3HMW | Psoriasis            | 2009      | Phase M  |
|   |                                |                       |           |            |                |              | Psoriatic arthritis  | 2013      | Phase M  |
|   |                                |                       |           |            |                |              | Multiple sclerosis   |           | Phase II |
|   |                                |                       |           |            |                |              | Crohn's disease      |           | Phase II |

**Table 3**

Summary of the clusters of the common ‘aggregation-prone’ regions in the antibodies used for this study. The clusters of the ‘aggregation-prone’ regions, the ‘aggregation-prone’ regions, the chain, the specific peptides for each region (the amino acids that were substituted are in bold letters and underlined) and the final results after the substitutions (the ‘aggregation-prone’ peptides that were eliminated completely are depicted with (√) and the ones that remain are shown).

| Clusters | Regions           | Chain | Peptides                                           | After Substitutions   |
|----------|-------------------|-------|----------------------------------------------------|-----------------------|
| Cluster1 | RVTITC            | LIGHT | RV <u><b>T</b></u> ITC                             | √                     |
|          |                   | LIGHT | RV <u><b>T</b></u> ITC                             | √                     |
| Cluster1 | [FY]T[FL]TISS     | LIGHT | FTFTI <u><b>S</b></u> S                            | FTFTI <u><b>S</b></u> |
|          |                   | LIGHT | F <u><b>T</b></u> LT <u><b>I</b></u> S             | √                     |
| Cluster2 | I[VL]LTQ          | LIGHT | I <u><b>L</b></u> LTQ                              | √                     |
|          |                   | LIGHT | I[VL] <u><b>L</b></u> TQ                           | √                     |
| Cluster2 | [AV]ILS[AV]       | LIGHT | [AV] <u><b>I</b></u> LS[AV]                        | √                     |
| Cluster3 | PSVFIF            | LIGHT | PSV <u><b>F</b></u> IF                             | √                     |
|          |                   | LIGHT | PSV <u><b>F</b></u> IF                             | √                     |
|          |                   | LIGHT | P <u><b>S</b></u> VFIF                             | FI                    |
| Cluster3 | TASVVCLNNFY       | LIGHT | <u><b>T</b></u> ASVVCLNNFY                         | SVVCLNN               |
|          |                   | LIGHT | <u><b>T</b></u> ASVVCLNNFY                         | SVVCLNNF              |
| Cluster3 | YSLSSVTV          | HEAVY | <u><b>Y</b></u> SLSSV <u><b>T</b></u> V            | √                     |
| Cluster3 | GTQTYICNVN        | HEAVY | GTQ <u><b>T</b></u> YICNVN                         | √                     |
|          |                   | HEAVY | GTQ <u><b>T</b></u> YICNVN                         | √                     |
|          |                   | HEAVY | GT <u><b>Q</b></u> TYICNV                          | √                     |
|          |                   | HEAVY | <u><b>T</b></u> Y <u><b>T</b></u> C                | √                     |
| Cluster4 | A[TV]YYC          | LIGHT | A <u><b>T</b></u> YYC                              | √                     |
|          |                   | LIGHT | A <u><b>T</b></u> Y <u><b>Y</b></u> C              | √                     |
|          |                   | LIGHT | A <u><b>V</b></u> YYC                              | √                     |
| Cluster5 | [TS]A[VIL]YYC     | HEAVY | TA <u><b>V</b></u> YYC                             | YYC                   |
|          |                   | HEAVY | <u><b>S</b></u> A <u><b>V</b></u> YYC              | √                     |
|          |                   | HEAVY | A <u><b>V</b></u> YYC                              | √                     |
|          |                   | HEAVY | <u><b>T</b></u> A <u><b>V</b></u> YYC              | √                     |
|          |                   | HEAVY | TA <u><b>I</b></u> YYC                             | √                     |
|          |                   | HEAVY | <u><b>T</b></u> A <u><b>L</b></u> YYC              | A <u><b>L</b></u> YY  |
| Cluster5 | G[TS][TL]VTVS[SA] | HEAVY | GT <u><b>L</b></u> VTVS[SA]                        | √                     |
|          |                   | HEAVY | GT <u><b>T</b></u> VTVS[SA]                        | √                     |
|          |                   | HEAVY | <u><b>T</b></u> LT <u><b>V</b></u> <u><b>S</b></u> | √                     |
|          |                   | HEAVY | GS <u><b>L</b></u> VTVS[SA]                        | √                     |
|          |                   | HEAVY | GT <u><b>L</b></u> VTV <u><b>S</b></u>             | √                     |
| BURIED   | GCLVK             | HEAVY | GCLVK                                              | GCLVK                 |
| BURIED   | W[IVL][GSA]       | HEAVY | W[IVL][GSA]                                        | W[IVL][GSA]           |



Fig. 1



Fig. 2




Fig. 3